Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia

被引:0
|
作者
Sushil G. Rane
Pierre Dubus
Richard V. Mettus
Elizabeth J. Galbreath
Guenther Boden
E. Premkumar Reddy
Mariano Barbacid
机构
[1] Fels Institute for Cancer Research and Molecular Biology,Division of Endocrinology
[2] Temple University School of Medicine,undefined
[3] Laboratoire d'Histologie–Embryologie,undefined
[4] Université Victor Ségalen,undefined
[5] Eli Lilly & Co.,undefined
[6] Diabetes and Metabolism and the General Clinical Research Center,undefined
[7] Temple University School of Medicine,undefined
[8] Centro Nacional de Investigaciones Oncológicas Carlos III,undefined
来源
Nature Genetics | 1999年 / 22卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To ascertain the role of cyclin-dependent kinase 4 (Cdk4) in vivo, we have targeted the mouse Cdk4 locus by homologous recombination to generate two strains of mice, one that lacks Cdk4 expression and one that expresses a Cdk4 molecule with an activating mutation. Embryonic fibroblasts proliferate normally in the absence of Cdk4 but have a delayed S phase on re-entry into the cell cycle. Moreover, mice devoid of Cdk4 are viable, but small in size and infertile. These mice also develop insulin-deficient diabetes due to a reduction in β-islet pancreatic cells. In contrast, mice expressing a mutant Cdk4 that cannot bind the cell-cycle inhibitor P16INK4a display pancreatic hyperplasia due to abnormal proliferation of β-islet cells. These results establish Cdk4 as an essential regulator of specific cell types.
引用
收藏
页码:44 / 52
页数:8
相关论文
共 50 条
  • [21] MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2
    M P Gillam
    D Nimbalkar
    L Sun
    K Christov
    D Ray
    P Kaldis
    X Liu
    H Kiyokawa
    Oncogene, 2015, 34 : 932 - 938
  • [22] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Javier Martin-Broto
    Jeronimo Martinez-Garcia
    David S. Moura
    Andres Redondo
    Antonio Gutierrez
    Antonio Lopez-Pousa
    Javier Martinez-Trufero
    Isabel Sevilla
    Roberto Diaz-Beveridge
    Maria Pilar Solis-Hernandez
    Amancio Carnero
    Marco Perez
    David Marcilla
    Jesus Garcia-Foncillas
    Pablo Romero
    Javier Fernandez-Jara
    Daniel Lopez-Lopez
    Ivan Arribas
    Nadia Hindi
    Signal Transduction and Targeted Therapy, 8
  • [23] MDM2 and CDK4 expression in periosteat osteosarcoma
    Righi, Alberto
    Gambarotti, Marco
    Benini, Stefania
    Gamberi, Gabriella
    Cocchi, Stefania
    Picci, Piero
    Bertoni, Franco
    HUMAN PATHOLOGY, 2015, 46 (04) : 549 - 553
  • [24] Expression and Clinical Significance of CREPT and CDK4 in Cervical Cancer
    Yao, Shenghui
    Sun, Huili
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2021, 50 (02) : 418 - 420
  • [25] Expression level of CDK4 in extramammary Paget's disease
    Kajihara, Ikko
    CANCER SCIENCE, 2018, 109 : 1339 - 1339
  • [26] Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/CDKN2A
    Martin-Broto, Javier
    Martinez-Garcia, Jeronimo
    Moura, David S.
    Redondo, Andres
    Gutierrez, Antonio
    Lopez-Pousa, Antonio
    Martinez-Trufero, Javier
    Sevilla, Isabel
    Diaz-Beveridge, Roberto
    Solis-Hernandez, Maria Pilar
    Carnero, Amancio
    Perez, Marco
    Marcilla, David
    Garcia-Foncillas, Jesus
    Romero, Pablo
    Fernandez-Jara, Javier
    Lopez-Lopez, Daniel
    Arribas, Ivan
    Hindi, Nadia
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [27] The structure of CDK4/cyclin D3 has implications for models of CDK activation
    Takaki, T.
    Echalier, A.
    Brown, N. R.
    Hunt, T.
    Endicott, J. A.
    Noble, M. E. M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (11) : 4171 - 4176
  • [28] Distinct roles for Cdk4 and Cdk6 during B lymphocyte activation.
    Tanguay, DA
    Chiles, TC
    FASEB JOURNAL, 1996, 10 (06): : 120 - 120
  • [29] Targeting the cell cycle - Beyond CDK4/6 inhibition
    Jeselsohn, R.
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Expression and therapeutic implications of cyclin dependent kinase 4 (CDK4) in osteosarcoma
    Zhou, Yubing
    Hornicke, Francis
    Duan, Zhenfeng
    CANCER RESEARCH, 2017, 77